Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematologic Malignancy: early-phase trial registry
37 of 49 indexed Hematologic Malignancy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #281 of 28,707 conditions by registered trial count.
49 US clinical trials · 37 currently recruiting · #281 of 28,707 conditions by registered trial count
Hematologic Malignancy: 49 US clinical trials tracked, 37 recruiting.
Hematologic Malignancy is the subject of 49 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 6 of these trials.
Enrollment posture brief
Registry condition hematologic-malignancy
OPEN 37 | RECR 76% | LATE 1 | EARLY 18 | RANK #281 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Hematologic Malignancy lists 37 open slots (76% of 49 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematologic Malignancy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematologic Malignancy is recruiting above its size-band peers.
37 of 49 indexed trials (75.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hematologic Malignancy trials is spread across many organizations.
St. Jude Children's Research Hospital accounts for 6 of 49 trials (12.2%). 34 distinct sponsors appear on at least one study for this condition label.
-
Most Hematologic Malignancy trials plan to enrol fewer than 100 people.
Median target enrolment is 57 among the 49 trials that report a genuine target (sentinel values excluded). 36 of those (73.5%) plan for fewer than 100 participants.
-
Hematologic Malignancy research is mostly interventional.
36 interventional and 13 observational studies make up this index (73.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
49 total, page 1 of 1
Global Cardio Oncology Registry
The Cleveland Clinic
NCT05598879
Immune Profiling for Cancer Immunotherapy Response
Dartmouth-Hitchcock Medical Center
NCT06116032
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Massachusetts General Hospital
NCT06472089
HEME Home Transfusion Program
Dana-Farber Cancer Institute
NCT06487247
Mosaic Trial for Stem Cell Transplant Recipients
Northwestern University
NCT06960993
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology
NCT06001788
Implementation of an Oral Chemotherapy Adherence Intervention
UNC Lineberger Comprehensive Cancer Center
NCT06989489
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
Wake Forest University Health Sciences
NCT07203534
Response to Influenza Vaccination in Pediatric Oncology Patients
St. Jude Children's Research Hospital
NCT05384288
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
St. Jude Children's Research Hospital
NCT06579469
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Massachusetts General Hospital
NCT05646576
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
National Cancer Institute (NCI)
NCT06856226
Diet and Cognitive Training in Hematologic Cancer Survivors
University of Alabama at Birmingham
NCT05708716
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT05735717
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
Wake Forest University Health Sciences
NCT03890614
Intervention for Fatigue in HCT Recipients
Massachusetts General Hospital
NCT05715047
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
Washington University School of Medicine
NCT06689800
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
Duke University
NCT06532773
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
NCT07257419
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis Pharmaceuticals
NCT06401356
Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies
Duke University
NCT05397132
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
Nationwide Children's Hospital
NCT06082947
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT07006506
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X
NCT06462365
A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy
Aperture Medical Technology
NCT05583734
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
Mayo Clinic
NCT06566209
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT07052370
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
NCT06131801
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
NCT05529069
Home Blood Transfusions
Thomas Jefferson University
NCT07121140
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
NCT07044544
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Joshua Sasine, MD, PhD
NCT05887167
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
Northside Hospital
NCT05417971
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
NCT06326463
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Duke University
NCT06731504
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06398457
Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant
Massachusetts General Hospital
NCT05709912
Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers
City of Hope Medical Center
NCT02041416
Expressive Writing Program Among Young Adults With Blood Cancer
Blood Cancer United
NCT07413991
A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors
Brigham and Women's Hospital
NCT06153797
Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation
Garcia, Jose M., MD, PhD
NCT02990130
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Memorial Sloan Kettering Cancer Center
NCT04552288
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
St. Jude Children's Research Hospital
NCT05164016
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
NCT04395222
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
Nationwide Children's Hospital
NCT03431090
Mindfulness and CBT for Sleep
Duke University
NCT04736056
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
Medical College of Wisconsin
NCT03699631
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Joanne Kurtzberg, MD
NCT00673114
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematologic Malignancy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematologic Malignancy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematologic Malignancy page
49 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Hematologic Malignancy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Hematologic Malignancy trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematologic Malignancy condition card totals 49 registered trials; most-linked intervention Fludarabine; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.